Compare Heron Therapeutics Inc (HRTX) vs Somnigroup International Inc. Common Stock (SGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Somnigroup International Inc. Common Stock — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $74.18M), while Somnigroup International Inc. Common Stock trades at $62.83 (market cap $14.48B). The key difference: Somnigroup International Inc. Common Stock is far larger — about 195.2× Heron Therapeutics Inc's market cap, and Somnigroup International Inc. Common Stock pays a 1.08% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 36 Days and Somnigroup International Inc. Common Stock for 0 Days on average.
| HRTX | SGI | |
|---|---|---|
Market Cap | $74.18M | $14.48B |
Volume | 1,857,401 | 1,734,399 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $97.99 |
52-Week Low | $0.27 | $61.49 |
Typical Hold Time | 36 Days | 0 Days |
Enterprise Value | $180.92M | $20.78B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3906, down 6.02% today, with a bullish technical signal from moving averages and oscillators. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates. Despite a high gross margin of 70.07%, it posted a net loss of -$20.20 million in 2025. Analyst consensus is strongly positive with 17 buy ratings. Recent news highlights earnings results and competitive comparisons.
The outlook remains speculative given persistent losses and negative ROE, but strong analyst support and improving cash flow trends offer potential upside. Key risks include profitability challenges and revenue volatility. Investors should weigh the bullish sentiment against fundamental weaknesses.
Somnigroup International (SGI) trades at $62.87, up 0.75% with neutral technical signals. The company shows strong profitability with 44.24% gross margins and has beaten earnings estimates for three consecutive quarters. Recent acquisition of Leggett & Platt enhances vertical integration with $75M synergy target. Analyst consensus is strongly bullish with 91% buy ratings and $94.50 price target, representing 50% upside potential from current levels.
SGI presents compelling growth prospects through strategic acquisitions and operational efficiencies, though faces margin pressures in weak bedding markets. The stock trades at reasonable valuations (P/E 24.85) with improving cash flow trends expected in 2026. Key risks include integration execution and market competition, but strong institutional interest and insider buying support the bullish case.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Somnigroup International Inc. Common Stock
Somnigroup International Inc. (formerly Tempur Sealy International) is a bedding and sleep-products company that designs, manufactures, distributes, and retails mattresses and related products. It operates through Tempur Sealy North America, Tempur Sealy International, and Mattress Firm, with brands including Tempur-Pedic, Sealy, Stearns & Foster, and Mattress Firm.
Read more on SGI →
